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Introduction
The human restricted bacteria, Salmonella enterica serovar 
Typhi is the major cause of  typhoid fever (or enteric 
fever), a characteristic severe systemic illness [1]. In 2010, 
typhoid fever accounted for an estimated global burden of  
27 million new cases and 200,000 deaths [2].
For over two decades, S. enterica serovar Typhi and other 
serovars have developed resistance to the first line 
antimicrobials (ampicillin, chloramphenicol, and co-
trimoxazole). As a result of  this multidrug resistance 
(MDR), quinolones became key antibiotics for treatment 
of  Salmonella Typhi disease [3]. Quinolones are a group 
of  antimicrobials with a 4-quinolone nucleus [4]. 
Quinolones target the bacterial enzymes DNA gyrase and 
topoisomerase IV, which are essential for DNA replication 
and transcription [4]. They are classified by differences in 
their in-vitro antimicrobial activity into: 
First-generation (nalidixic acid and cinoxacin), • 
Second-generation (norfloxacin, ciprofloxacin, • 
lomefloxacin, ofloxacin, and levofloxacin), 
Third-generation (sparfloxacin, gatifloxacin, and • 
grepafloxacin), and 
Fourth-generation (trovafloxacin, moxifloxacin, and • 
gemifloxacin)[5].
The second, third, and fourth-generation quinolones are 
also called fluoroquinolones, generated by addition of  a 
fluorine atom and a cyclic diamine piperazine at C6 and 
C7 positions of  the 4-quinolone nucleus respectively [4].
The second-generation quinolones have an expanded 
gram-negative and atypical coverage but limited gram-
positive coverage, while the third-generation additionally 
have improved gram-positive coverage, and the fourth-
generation have an additional anaerobic coverage [6].
Nalidixic acid was commonly used especially in 
developing countries but as a result of  resistance and 
toxicity, ciprofloxacin became the most commonly used 
against Salmonella  Typhi. However, in-vitro resistance to 
nalidixic acid in Salmonella Typhi also indicates resistance 
to ciprofloxacin [7]. 
Due to lack of  availability and cost, other higher generation 
quinolones are not used in resource-limited countries. 
Ofloxacin, levofloxacin, moxifloxacin, and gatifloxacin 
are also used in the treatment of  MDR tuberculosis; this 
could also be a reason for lack of  their use in countries 
where tuberculosis is prevalent. 
This review focuses on the mechanisms underlying 
susceptibility and resistances of  quinolones in Salmonella 
Typhi; explaining the factors driving the spread of  
resistance, current epidemiological trends and clinical 
significance of  the resistance. 
Methodology 
Articles for this review were identified by searches of  
PubMed, Web of  Science, Science Direct, Scopus, Global 
Health Database, and the Liverpool School of  Tropical 
Medicine electronic library ‘DISCOVER’ using the search 
terms “salmonella Typhi”, “quinolones”, and “resistance”. 
Only articles published in English between 2002 and 2015 
were used.
Mutations of gyrase and topoisomerase genes 
The primary target of  quinolones in gram-negative bacteria 
is the gyrA subunit of  DNA gyrase, and point mutations 
usually occur within the quinolone resistance determining 
region (QRDR) of  the DNA gyrase gene [4].  In Salmonella 
Typhi, single mutation of  gyrA gene leads to resistance to 
nalidixic acid and reduced susceptibility to ciprofloxacin 
[minimum inhibitory concentration (MICs) of  0.125–
0.25μg/mL], whereas complete resistance to ciprofloxacin 
(MIC > 4μg/mL) is caused by double mutation in the 
QRDR region [3]. A non-classical quinolone resistance 
in Salmonella Typhi exhibiting a gyrB gene mutation also 
exists [8]. In Gram-negative bacteria, point mutations in 
topoisomerase IV subunit genes parC and parE also occur, 
but are less common than gyrA mutations [4]. 
Efflux-based drug resistance
Bacteria have the ability to increase the expression of  
nonspecific energy-dependent efflux pumps that avoid 
the accumulation of  effective intracellular concentrations 
of  quinolones by actively pumping the drug across the cell 
membrane, thus leading to an efflux-based drug resistance 
[4]. Efflux-based drug resistance can also be caused by 
mutation in a drug transporter [9]. Salmonella Typhi 
expresses MDR transporters of  the major facilitator super-
family (MFS), which include STY4874 proton-dependent 
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efflux pump that transports several quinolones [9]. 
STY4874 pump is considered significant because it 
pumps quinolones out of  the cells and is the most 
likely MDR transporter, as it confers resistance to 
quinolones, aminoglycosides and chloramphenicol. 
Efflux-mediated quinolone resistance becomes 
of  clinical significance only when combined with 
other resistance mechanisms, such as mutations in 
target enzymes because they only produce low-level 
resistance [4].
Reduced outer membrane permeability
Gram-negative bacteria develop antimicrobial 
resistance (including quinolones) by reducing the 
levels of  outer membrane porins that form the 
routes responsible for passive diffusion. This 
results in reduced outer membrane permeability to 
antimicrobials [4]. It has been shown that exposure 
of  non-dividing cells to ciprofloxacin results in 
‘adaptive mutation’ of  the cells, thus resulting 
in decreased permeability of  the bacterial outer 
membrane. This is considered to be a cause of  gradual 
increase in mean MIC for ciprofloxacin in Salmonella Typhi 
[10]. 
Plasmid-mediated resistance
The plasmid-encoded gnr gene is a naturally occurring 
gene which can mediate reduced susceptibility to 
quinolones, but it can cause a higher level of  resistance 
by potentiating the effect of  other resistance mutations 
[4]. Plasmid gene qnrB and qnrS in Salmonella Typhi were 
shown to be responsible for plasmid-mediated quinolone 
resistance [11]. 
Biofilm
Biofilm does not affect drug resistance in Salmonella Typhi 
but results in delayed clearance from typhoid patients 
[12].
Factors contributing to the spread of resistance and 
epidemiological trends 
The current global Salmonella Typhi resistance to quinolones 
emerged as a result of  extensive quinolone use/misuse, 
including selective pressure from empirical use[13]. The 
use of  substandard fluoroquinolones and their usage in 
animals also significantly contributed to the resistance 
[14, 15]. Three trends of  antimicrobial resistance to 
Salmonella Typhi occurred as a result of  ciprofloxacin use: 
(i) ongoing resistance to the first-line antimicrobials and 
low prevalence of  quinolone-resistant Salmonella Typhi, 
(ii) equal prevalence of  nalidixic acid-resistant Salmonella 
Typhi, and (iii) a slow increase of  nalidixic acid-resistant 
Salmonella Typhi (NARST) and reduced prevalence of  
multidrug-resistant Salmonella Typhi (MDRST)[13]- see 
Figure 1.
Most of  the resistant strains of  Salmonella Typhi (especially 
the haplotype H58, a prevalent MDR clone that has spread 
over Asia and Africa) emerged from Southeast Asia and 
then spread to other regions of  the world [13]. Travellers 
also played a significant role in spreading the resistant 
Salmonella Typhi, especially to the developed world [16, 
17]. The quinolone-resistant Salmonella Typhi is not only 
prevalent in hospital settings but also in the community 
[18].
Clinical significance and conclusion 
Enteric fever caused by NARST isolates which also have 
reduced susceptibility to ciprofloxacin are associated with 
poor clinical outcomes including treatment failure [18]. 
These isolates are usually classified as being ciprofloxacin 
susceptible when using the previous susceptibility 
breakpoints for ciprofloxacin [18]. However in order to 
avoid such misclassifications, the clinical and laboratory 
standard institute (CLSI) approved a reduced susceptibility 
breakpoint for Salmonella Typhi (≤0.06 μg/mL) and also 
suggested that the nalidixic acid screen should be used 
to test for reduced quinolone susceptibility in Salmonella 
Typhi, although it may miss other quinolone resistant 
strains[19]. Therefore ciprofloxacin MIC is a significant 
determinant of  clinical response to treatment and it 
should be considered in all Salmonella Typhi isolates [20].
Convalescent faecal carriage as a result of  quinolone-
resistant Salmonella Typhi plays a critical role in spreading 
the disease in the community [21]. This is difficult to 
control especially in countries where there is limited access 
to adequate sanitation and clean water facilities. 
Although not available in many resource-limited settings, 
a community-based drug susceptibility data is critically 
needed to facilitate rational use of  antimicrobials in 
general and improve antimicrobial choices made for 
enteric fever.  
Third-generation cephalosporins and azithromycin remain 
the treatment of  choice for typhoid fever in areas with 
quinolone resistance and for travellers returning from 
these areas [17]. There is some evidence supporting the 
effectiveness of  newer fluoroquinolones (gatifloxacin) in 
areas where resistance to nalidixic acid and ciprofloxacin 
Figure 1. Emergence and global resistance trends of Salmonella Typhi to nalidixic 
acid and ciprofloxacin. Data from Tatavarthy et al. 2014. – see reference 13. 
*Indicates foreign travel related.
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exist [22]. However, cheaper oral quinolones such as 
ciprofloxacin can still be used where there is evidence of  
absence of  Salmonella Typhi resistance. Prevention through 
access to clean and safe water, adequate sanitation, and 
education should be encouraged in all settings. A recent 
Cochrane review showed that both the licensed Ty21a and 
Vi polysaccharide vaccines and the unlicensed Vi-rEPA 
vaccine are efficacious [23].  However, their role-out on 
a large scale, especially in resource-limited settings where 
typhoid fever is endemic, would be a significant challenge, 
although travellers to those areas may benefit. 
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